Intrathecal Administration of Tempol Reduces Chronic Constriction Injury-Induced Neuropathic Pain in Rats by Increasing SOD Activity and Inhibiting NGF Expression

Cell Mol Neurobiol. 2016 Aug;36(6):893-906. doi: 10.1007/s10571-015-0274-7. Epub 2015 Oct 3.

Abstract

We investigate the antinociceptive effect of intrathecal and intraperitoneal tempol administration in a rat model of chronic constriction injury (CCI)-induced neuropathic pain and explore the underlying antinociceptive mechanisms of tempol. Rats were randomly assigned to four groups (n = 8 per group): sham group, CCI group, Tem1 group (intrathecal injection of tempol), and Tem2 group (intraperitoneal injection of tempol). Neuropathic pain was induced by CCI of the sciatic nerve. Tempol was intrathecally or intraperitoneally administered daily for 7 days beginning on postoperative day one. The mechanical withdrawal threshold and thermal withdrawal latency were tested on preoperative day 3 and postoperative days 1, 3, 5, 7, 10, 14, and 21. Structural changes were examined by hematoxylin and eosin staining, toluidine blue staining, and electron microscopy. Malondialdehyde (MDA) and superoxide dismutase (SOD) levels were determined using the thiobarbituric acid and nitroblue tetrazolium methods, respectively. Nerve growth factor (NGF) expression levels were determined by immunohistochemistry and Western blot. Intrathecal, but not intraperitoneal, injection of tempol produced a persistent antinociceptive effect. Intraperitoneal injection of tempol did not result in high enough concentration of tempol in the cerebrospinal fluid. Intrathecal, but not intraperitoneal, injection of tempol inhibited CCI-induced structural damage in the spinal cord reduced MDA levels, and increased SOD activities in the spinal cord. Furthermore, intrathecal, but not intraperitoneal, injection of tempol further downregulated the expression of NGF in the spinal cord following CCI, and this effect was blocked by p38MAPK inhibitor. Intrathecal injection of tempol produces antinociceptive effects and reduces CCI-induced structural damage in the spinal cord by increasing SOD activities and downregulating the expression of NGF via the p38MAPK pathway. Intraperitoneal administration of tempol does not exhibit antinociceptive effects.

Keywords: Neuropathic pain; Neurotrophic factor; Oxidative stress; Spinal cord; Tempol.

MeSH terms

  • Animals
  • Constriction
  • Cyclic N-Oxides / administration & dosage
  • Cyclic N-Oxides / pharmacology*
  • Injections, Spinal / methods
  • Male
  • Nerve Growth Factor / metabolism*
  • Neuralgia / drug therapy
  • Neuralgia / metabolism*
  • Pain Threshold / drug effects
  • Rats, Sprague-Dawley
  • Sciatic Nerve / drug effects*
  • Sciatic Nerve / injuries
  • Spin Labels
  • Spinal Cord / drug effects
  • Spinal Cord / metabolism
  • Spinal Cord / ultrastructure
  • Superoxide Dismutase / metabolism*

Substances

  • Cyclic N-Oxides
  • Spin Labels
  • Nerve Growth Factor
  • Superoxide Dismutase
  • tempol